NEW YORK, March 5, 2021 /PRNewswire/ -- TMRW Life Sciences,
Inc. ("TMRW"), the creator of the world's first and only automated
technology platform for the management, identification, and storage
of frozen eggs and embryos, announces today that Brian E. Miller, PhD, is joining TMRW's senior
leadership team as Senior Vice President of Sales.
In his role, Brian will be responsible for bringing TMRW's
innovative technology to fertility clinics in the United States. Brian will also be integral
to the ongoing development of new products and services that will
expand TMRW's offerings, enabling fertility clinics to further
enhance and automate their clinical lab operations.
A veteran of the fertility industry, Brian has over 25 years of
experience at the nexus of science and technology, scaling
fertility products and solutions and bringing them to market to
improve patient care. Brian has an extensive background in biotech
and pharma sales, medical affairs, medical practice operations,
business development, government affairs, clinical laboratory and
research, and alliance partner management. Brian has a profound
understanding of the clinicians and patients who he works with,
which has allowed him to foster deep and long-lasting relationships
with his clients.
Brian joins TMRW from CooperSurgical, the fertility, genomics,
and women's health division of The Cooper Companies (NYSE: COO),
where he led all fertility and genomic solutions and patient
advocacy for North America.
Previously, Brian was Chief Commercial Officer at Recombine, a
clinical genetic testing company specializing in carrier screening
which was acquired by CooperSurgical in 2016. He also served as
Chief Operating Officer at the Fertility Centers of New
England. Earlier in his career, Brian held multiple senior
positions at EMD Serono, where he helped lead a medical affairs
team and managed all U.S. strategic accounts for endocrinology and
fertility sales. At Organon, as a medical liaison, he
supported the science and launch of new products through
Brian began his career as an andrologist at the Hospital of
Central Connecticut, and advanced
to Associate Director of Clinical Research and reproductive
endocrinology and andrology lab supervisor. He completed a Ph.D.
from the University of Connecticut.
Alan Murray, TMRW's Founder and
Co-CEO commented: "Brian is one of the best known and most
respected executives in the fertility field. Over his two decade
career, he has won the trust and admiration of the leading
clinicians and innovators in not only the fertility space, but also
the many key intersecting disciplines such as genetic testing and
lab operations. We could not be more delighted by his arrival to
further TMRW's appeal to innovators in the fertility space."
"TMRW is leading the way in developing how IVF will be practiced
in the future," said Brian. "The automation revolution TMRW is
leading is already benefiting clinicians and patients alike. I'm
excited to join a team of innovators, who, in a short period of
time, took an extraordinary vision to bring safety to cryospecimen
management and developed a game-changing technology solution that
will become the community standard in IVF labs worldwide. I am
thrilled to be part of the ongoing innovation which is TMRW's
Brian's appointment comes on the heels of TMRW's commercial
launch in February 2021.
About TMRW Life Sciences, Inc.
TMRW has created the world's first automated platform designed
specifically for cryo-management of eggs and embryos used in IVF.
TMRW's RFID-enabled, complete digital chain of custody SaaS
technology radically improves upon the error-prone manual and
analog methods that have gone unchanged throughout the history of
IVF, significantly reducing the chances of implantation mix-ups or
loss of eggs and embryos. The TMRW team includes many of the
world's most celebrated innovators in fertility, embryology,
cryo-management, automation, software development and robotics to
name a few of the disciplines involved. TMRW's co-founders,
Joshua Abram, Alan Murray, and Dr. Jeffrey Port, are serial tech and life sciences
entrepreneurs. Their immediate prior ventures sold for a combined
sum of more than $1 billion. To date,
TMRW has raised $50 million. For more
information, please visit TMRW.org.
Grosser, Dini von Mueffling Communications
View original content to download
SOURCE TMRW Life Sciences